Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 3/10/09  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Phillip A. Furman

Wrong Dr. Phillip A. Furman?
 
Background

Employment History

Board Memberships and Affiliations

  • Chairman of the Admissions Committee
    Biochemistry and Journal of Biological Chemistry
  • Board Member
    Virology

Education

  • Ph.D.
  • doctorate , microbiology
    Tulane University
  • B.S. , Biology and Chemistry
    Piedmont College
  • M.A. , Microbiology
    University of South Florida
34 Total References
Web References
About Southern Capitol Ventures
www.southerncapitolventures.com, 10 Mar 2009 [cached]
Dr. Phil Furman
Phil is Vice President of Biological Sciences at Georgia-based Pharmasset, an emerging pharmaceutical company committed to the discovery, development, and commercialization of novel antiviral drugs. He is the former chief scientific officer for Triangle Pharmaceuticals, which was acquired for $464 million by Gilead Sciences (NASDAQ:GILD). The company developed new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus. The company had an existing portfolio of five licensed drug candidates and several drug candidates. Previously, he served as director of Virology at Burroughs Wellcome, where he played a significant role in the development of AZT, acycolvir, abacavir, valtrex and agenerase and is listed as a co-inventor on over 20 patents. His research at Burroughs Wellcome focused on the structure and function of nucleic acid polymerizing enzymes. He is named co-inventor of the use of AZT for HIV therapy. He is the author of over 80 publications.
Phil continues to review articles for the following journals: Antimicrobial Agents and Chemotherapy, Biochemistry and Journal of Biological Chemistry and has been a section editor for Current Drugs. >From 1993-1995, he was a member of the scientific panel of the Inter-Company Collaboration for AIDS Drug Development and was the Chairman of the Admissions Committee for the organization. Phil received an M.A. in microbiology from the University of Southern Florida and a Ph.D. in microbiology from Tulane University and completed his post-doctoral training at Duke University.
...
Phil Furman, PhD
Triangle Pharmaceuticals, Inc. - Management
www.shocksmith.com, 13 June 2005 [cached]
Phillip A. Furman, Ph.D. Chief Scientific Officer.Previously, Dr. Furman served as Director of Virology at Burroughs Wellcome, where he played a significant role in the development of both AZT and acyclovir.Dr. Furman's research at Burroughs Wellcome focused on the structure and function of nucleic acid polymerizing enzymes.He is a named co-inventor of the use of AZT for HIV therapy.Dr. Furman received a B.S. in biology from Piedmont College, an M.A. in microbiology from the University of Southern Florida and a Ph.D. in microbiology from Tulane University.
Management Team - Pharmasset, Inc.
www.pharmasset.com, 15 Mar 2009 [cached]
Phillip A. Furman, Ph.D. - Vice President, Biological Sciences
Phillip A. Furman, Ph.D. is our Vice President, Biological Sciences and has been with Pharmasset since February 2004.From October 2001 to February 2004, Dr. Furman was a consultant for Bukwang Pharm.Co., Ltd. and other organizations.Prior to joining Pharmasset, Dr. Furman was a co-founder and the Chief Scientific Officer of Triangle Pharmaceuticals, an antiviral drug discovery and development company, which was acquired by Gilead Sciences.While at Triangle from 1995 to October 2001, he oversaw the activities of the virology group and reviewed antiviral and anticancer licensing candidates.During his 20-plus year tenure in drug discovery and development with Burroughs Wellcome, most recently as the Director of the Division of Virology from 1989 to 1995, Dr. Furman was a co-inventor of the use of Retrovir for the treatment of HIV and Epivir for the treatment of HBV.He has also been involved in the clinical development of numerous antiviral agents, including Zovirax (acyclovir), Retrovir, Emtriva, Ziagen, Agenerase (amprenavir) and Viroptic (trifluridine).Dr. Furman is an author of over 80 scientific publications, and he is named as an inventor on more than 20 patents.Dr. Furman received a B.S. in Biology and Chemistry from Piedmont College, an M.A. in Microbiology from the University of South Florida, and a Ph.D. in Microbiology from Tulane University.
Life Sciences Advisory Committee for Southern Capitol Ventures
www.southerncapitolventures.com, 2 June 2004 [cached]
Dr. Phillip FurmanPhillip serves as a consultant to several early stage life science companies and is the former Chief Scientific Officer for Triangle Pharmaceuticals which was acquired for $464 million by Gilead Sciences.The company developed new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus.The company had an existing portfolio of five licensed drug candidates and several drug candidates.Previously, he served as Director of Virology at Burroughs Wellcome, where he played a significant role in the development of AZT, acycolvir, abacavir, valtrex and agenerase and he listed as a co-inventor on over twenty (20) patents.His research at Burroughs Wellcome focused on the structure and function of nucleic acid polymerizing enzymes.He is named co-inventor of the use of AZT for HIV therapy.He is the co-author of over seventy (70) publications.Phillip continues to review articles for the following journals: Antimicrobial Agents and Chemotherapy, Biochemistry and Journal of Biological Chemistry and has been a section editor for Current Drugs.From 1993-1995, he was a member of the scientific panel of the Inter-Company Collaboration for AIDS Drug Development and was the Chairman of the Admissions Committee for the organization.Phillip received his B.S. in biology from Piedmont College, an M.A. in microbiology from the University of Southern Florida and a Ph.D. in microbiology from Tulane University and did his post-doctoral training at Duke University.
Southern Capitol Ventures
www.southerncapitolventures.com, 13 April 2007 [cached]
Dr. Phil Furman
Phil is Vice President of Biological Sciences at Georgia-based Pharmasset, an emerging pharmaceutical company committed to the discovery, development, and commercialization of novel antiviral drugs.He is the former chief scientific officer for Triangle Pharmaceuticals, which was acquired for $464 million by Gilead Sciences (NASDAQ:GILD).The company developed new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus.The company had an existing portfolio of five licensed drug candidates and several drug candidates.Previously, he served as director of Virology at Burroughs Wellcome, where he played a significant role in the development of AZT, acycolvir, abacavir, valtrex and agenerase and is listed as a co-inventor on over 20 patents.His research at Burroughs Wellcome focused on the structure and function of nucleic acid polymerizing enzymes.He is named co-inventor of the use of AZT for HIV therapy.He is the author of over 80 publications.
Phil continues to review articles for the following journals: Antimicrobial Agents and Chemotherapy, Biochemistry and Journal of Biological Chemistry and has been a section editor for Current Drugs. >From 1993-1995, he was a member of the scientific panel of the Inter-Company Collaboration for AIDS Drug Development and was the Chairman of the Admissions Committee for the organization.Phil received an M.A. in microbiology from the University of Southern Florida and a Ph.D. in microbiology from Tulane University and completed his post-doctoral training at Duke University.
...
Phil Furman, PhD
Other People with the name "Furman":
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304